Bio-Techne Corp. | Cash Flow

Fiscal year is July-June. All values USD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
110,948.00
107,735.00
104,476.00
76,086.00
126,150.00
Depreciation, Depletion & Amortization
19,175.00
37,226.00
42,764.00
60,036.00
64,463.00
Other Funds
262.00
615.00
566.00
20,819.00
65,885.00
Funds from Operations
138,603.00
150,726.00
158,911.00
159,172.00
168,471.00
Changes in Working Capital
1,841.00
11,367.00
15,041.00
15,451.00
1,896.00
Net Operating Cash Flow
136,762.00
139,359.00
143,870.00
143,721.00
170,367.00
Capital Expenditures
13,821.00
19,905.00
16,898.00
15,179.00
20,934.00
Purchase/Sale of Investments
172,664.00
13,466.00
776.00
36,990.00
49,393.00
Net Investing Cash Flow
49,688.00
426,493.00
107,570.00
305,954.00
38,712.00
Cash Dividends Paid - Total
45,394.00
47,106.00
47,607.00
47,325.00
47,973.00
Issuance/Reduction of Debt, Net
-
68,036.00
18,500.00
252,000.00
4,500.00
Net Financing Cash Flow
36,806.00
31,276.00
23,083.00
189,113.00
99,188.00
Net Change in Cash
154,782.00
264,036.00
9,705.00
27,375.00
30,378.00
Free Cash Flow
122,941.00
119,454.00
126,972.00
128,542.00
149,433.00
Deferred Taxes & Investment Tax Credit
2,853.00
1,304.00
2,624.00
3,433.00
46,716.00
Net Assets from Acquisitions
109,180.00
420,102.00
91,423.00
253,785.00
67,851.00
Other Sources
25.00
48.00
-
-
680.00
Change in Capital Stock
8,326.00
9,731.00
5,458.00
5,257.00
19,170.00
Exchange Rate Effect
5,138.00
8,178.00
3,512.00
495.00
2,089.00
Other Uses
-
-
25.00
-
-

About Bio-Techne

View Profile
Address
614 McKinley Place NE
Minneapolis Minnesota 55413
United States
Employees -
Website http://www.bio-techne.com
Updated 07/08/2019
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community.